Genetic factors influencing the outcome of early arthritis--the role of sulphoxidation status
- PMID: 1628166
- DOI: 10.1093/rheumatology/31.7.449
Genetic factors influencing the outcome of early arthritis--the role of sulphoxidation status
Abstract
A minority of individuals have an impaired ability to oxidize sulphur. An increased prevalence of this poor S-oxidation capacity has been observed in patients with established rheumatoid arthritis (RA). The role of this enzyme system in the development of disease was studied by testing the S-oxidation capacity of 54 patients with recent onset symmetrical poly-arthritis, who were followed up at 1 and 4 years. Those patients with persistent disease at 1 year had a prevalence of poor S-oxidation of 69%. At 4 years 74% of those with a diagnosis of RA were poor S-oxidizers compared to 31% of those who were asymptomatic (P less than 0.01). A defective ability to oxidize sulphur appears to predispose to persistent clinical disease.
Comment in
-
Genetic factors influencing the outcome of early arthritis--the role of sulphoxidation status.Br J Rheumatol. 1993 Feb;32(2):170-2. doi: 10.1093/rheumatology/32.2.170-a. Br J Rheumatol. 1993. PMID: 8428236 No abstract available.
Similar articles
-
Increased prevalence of poor sulphoxidation in patients with rheumatoid arthritis: effect of changes in the acute phase response and second line drug treatment.Ann Rheum Dis. 1992 Mar;51(3):318-20. doi: 10.1136/ard.51.3.318. Ann Rheum Dis. 1992. PMID: 1575574 Free PMC article.
-
The relationship of sulfoxidation status to efficacy and toxicity of penicillamine in the treatment of rheumatoid arthritis.Arthritis Rheum. 1990 Apr;33(4):574-7. doi: 10.1002/art.1780330416. Arthritis Rheum. 1990. PMID: 2328035
-
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3.J Rheumatol. 1984 Oct;11(5):626-32. J Rheumatol. 1984. PMID: 6334741
-
Management of early inflammatory arthritis. Genetic factors predicting persistent disease: the role of defective enzyme systems.Baillieres Clin Rheumatol. 1992 Jun;6(2):337-50. doi: 10.1016/s0950-3579(05)80178-5. Baillieres Clin Rheumatol. 1992. PMID: 1525843 Review.
-
Pharmacogenetics of the S-oxidation of S-carboxymethyl-L-cysteine.Drug Metabol Drug Interact. 1988;6(3-4):253-63. doi: 10.1515/dmdi.1988.6.3-4.253. Drug Metabol Drug Interact. 1988. PMID: 3078290 Review.
Cited by
-
Prognostic markers in rheumatoid arthritis and classification of antirheumatic therapies.Drugs. 1995;50 Suppl 1:15-25. doi: 10.2165/00003495-199500501-00004. Drugs. 1995. PMID: 8714795 Review.
-
Go it alone: four-electron oxidations by mononuclear non-heme iron enzymes.J Biol Inorg Chem. 2017 Apr;22(2-3):381-394. doi: 10.1007/s00775-016-1399-y. Epub 2016 Oct 25. J Biol Inorg Chem. 2017. PMID: 27783267 Free PMC article. Review.
-
Structure and mechanism of mouse cysteine dioxygenase.Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3084-9. doi: 10.1073/pnas.0509262103. Epub 2006 Feb 21. Proc Natl Acad Sci U S A. 2006. PMID: 16492780 Free PMC article.
-
The changing face of rheumatoid arthritis: sustained remission for all?Nat Rev Immunol. 2010 Aug;10(8):605-11. doi: 10.1038/nri2804. Nat Rev Immunol. 2010. PMID: 20651747 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical